Log in

NASDAQ:YTENYield10 Bioscience Stock Price, Forecast & News

+0.14 (+2.39 %)
(As of 05/29/2020 04:00 PM ET)
Today's Range
Now: $6.00
50-Day Range
MA: $5.26
52-Week Range
Now: $6.00
Volume92,122 shs
Average Volume120,101 shs
Market Capitalization$11.82 million
P/E RatioN/A
Dividend YieldN/A
Yield10 Bioscience, Inc., an agricultural bioscience company, engages in developing disruptive technologies for enhancing crop yield in the United States and Canada. The company, through its Smart Carbon Grid for Crops and T3 platforms, is involved in improving fundamental crop yield through enhanced photosynthetic carbon capture, as well as increased carbon utilization efficiency to increase seed yield. The company was formerly known as Metabolix, Inc. and changed its name to Yield10 Bioscience, Inc. in January 2017. Yield10 Bioscience, Inc. was founded in 1992 and is headquartered in Woburn, Massachusetts.
Read More
Yield10 Bioscience logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.3Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.25 out of 5 stars

Industry, Sector and Symbol

Industry Miscellaneous plastics products
Current SymbolNASDAQ:YTEN



Sales & Book Value

Annual Sales$810,000.00
Book Value$4.73 per share


Net Income$-12,960,000.00
Net Margins-1,660.40%


Market Cap$11.82 million
Next Earnings Date8/10/2020 (Estimated)
OptionableNot Optionable

Receive YTEN News and Ratings via Email

Sign-up to receive the latest news and ratings for YTEN and its competitors with MarketBeat's FREE daily newsletter.

Yield10 Bioscience (NASDAQ:YTEN) Frequently Asked Questions

How has Yield10 Bioscience's stock been impacted by COVID-19 (Coronavirus)?

Yield10 Bioscience's stock was trading at $4.82 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, YTEN shares have increased by 24.5% and is now trading at $6.00. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Yield10 Bioscience?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Yield10 Bioscience in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Yield10 Bioscience.

When is Yield10 Bioscience's next earnings date?

Yield10 Bioscience is scheduled to release its next quarterly earnings announcement on Monday, August 10th 2020. View our earnings forecast for Yield10 Bioscience.

How were Yield10 Bioscience's earnings last quarter?

Yield10 Bioscience Inc (NASDAQ:YTEN) posted its quarterly earnings data on Thursday, May, 14th. The specialty chemicals company reported ($2.12) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($1.97) by $0.15. The specialty chemicals company had revenue of $0.18 million for the quarter. Yield10 Bioscience had a negative return on equity of 464.23% and a negative net margin of 1,660.40%. View Yield10 Bioscience's earnings history.

When did Yield10 Bioscience's stock split? How did Yield10 Bioscience's stock split work?

Yield10 Bioscience's stock reverse split before market open on Thursday, January 16th 2020. The 1-40 reverse split was announced on Wednesday, January 15th 2020. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, January 15th 2020. An investor that had 100 shares of Yield10 Bioscience stock prior to the reverse split would have 3 shares after the split.

What price target have analysts set for YTEN?

3 brokerages have issued 1 year target prices for Yield10 Bioscience's stock. Their forecasts range from $10.00 to $80.00. On average, they expect Yield10 Bioscience's share price to reach $35.50 in the next year. This suggests a possible upside of 491.7% from the stock's current price. View analysts' price targets for Yield10 Bioscience.

What are Wall Street analysts saying about Yield10 Bioscience stock?

Here are some recent quotes from research analysts about Yield10 Bioscience stock:
  • 1. According to Zacks Investment Research, "Yield10 Bioscience, Inc. is an agricultural bioscience company. It focuses on the development of disruptive technologies for improvement in crop yield to enhance global food security. The company is working on new approaches, to improve fundamental elements of plant photosynthetic efficiency and optimizing carbon metabolism for better production. It operates primarily in Saskatoon, Saskatchewan, Canada. Yield10 Bioscience, Inc., formerly known as Metabolix, Inc., is based in Woburn, Massachusetts. " (3/28/2020)
  • 2. National Securities analysts commented, " Additional Genes Now Under Consideration. The research license with Bayer (STU: BAY – NR - €66.48) has been amended to include an expanded scope for the C3004 trait. Under the original agreement signed in late 2017, BAY considered the C3003 and C3004 traits for evaluation in soybean, with the genes under consideration targeted to controlling carbon flow. With YTEN’s additional discoveries in the C3004 trait from 2018 trials in camelina, the research license was expanded to include a broader scope of genes.
     A Validation Of Technology? We expect that since the December 2017 license was signed that BAY has studied the C3003 and C3004 traits within its soybean varieties in greenhouse settings, and moved to field trials in Spring 2019. We believe that BAY could easily terminate the agreement if it saw no commercial potential, and we believe the expanded scope represents a validation of YTEN technology.
     No Better Commercial Partner. Following BAY’s acquisition of Monsanto, it controls roughly one third of global soybean sales, and its overall market share is significantly greater when considering seed distributed by peers which include BAY licensed traits. We believe of the major commercial crops that there is no better partner for YTEN than BAY and its soybean market.
     Additional Agreements Needed, May Come With Funded R&D. We anticipate that YTEN is in active discussions with other commercial partners and believe future research agreements may come with a funded R&D component." (8/20/2019)
  • 3. Aegis analysts commented, "We expect a repeat on 2018 field trials with positive results, especially within C3003 in canola and camelina which should help YTEN pull forward collaboration with the company’s large AG major partners. In addition to canola and camelina, YTEN is also engaged with third parties interested in corn, soybean, wheat, and rice. The Trait Factory" is helping to broaden YTEN’s product portfolio. The company has identified three new sectors which could present additional opportunities for for long-term growth; PHA Pharmaceuticals (CBD). We believe the company’s broadening of its core assets as a positive. YTEN expects commercialization could occur within six years, as discussions are ongoing with possible partners." (8/13/2019)

Has Yield10 Bioscience been receiving favorable news coverage?

Media headlines about YTEN stock have trended positive this week, InfoTrie Sentiment reports. The research group rates the sentiment of press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Yield10 Bioscience earned a media sentiment score of 2.8 on InfoTrie's scale. They also gave news stories about the specialty chemicals company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the company's share price in the immediate future. View the latest news aboutYield10 Bioscience.

Are investors shorting Yield10 Bioscience?

Yield10 Bioscience saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 157,000 shares, an increase of 214.0% from the April 30th total of 50,000 shares. Based on an average daily trading volume, of 763,400 shares, the days-to-cover ratio is presently 0.2 days. Currently, 26.0% of the shares of the company are short sold. View Yield10 Bioscience's Current Options Chain.

Who are some of Yield10 Bioscience's key competitors?

What other stocks do shareholders of Yield10 Bioscience own?

Who are Yield10 Bioscience's key executives?

Yield10 Bioscience's management team includes the following people:
  • Dr. Oliver P. Peoples, Co-Founder, Pres, CEO & Director (Age 61)
  • Dr. Anthony J. Sinskey, Co-Founder & Director (Age 79)
  • Dr. Kristi Snell, VP of Research & Chief Science Officer (Age 51)
  • Ms. Lynne H. Brum, VP of Planning & Communications and Sec. (Age 55)
  • Mr. Charles B. Haaser, VP of Fin., Chief Accounting Officer & Treasurer (Age 63)

What is Yield10 Bioscience's stock symbol?

Yield10 Bioscience trades on the NASDAQ under the ticker symbol "YTEN."

Who are Yield10 Bioscience's major shareholders?

Yield10 Bioscience's stock is owned by many different institutional and retail investors. Top institutional investors include Cannell Peter B & Co. Inc. (2.76%) and BlackRock Inc. (1.96%). Company insiders that own Yield10 Bioscience stock include Jack W Schuler and Oliver P Peoples. View institutional ownership trends for Yield10 Bioscience.

Which major investors are selling Yield10 Bioscience stock?

YTEN stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc.. View insider buying and selling activity for Yield10 Bioscience.

Which major investors are buying Yield10 Bioscience stock?

YTEN stock was acquired by a variety of institutional investors in the last quarter, including Cannell Peter B & Co. Inc.. Company insiders that have bought Yield10 Bioscience stock in the last two years include Jack W Schuler, and Oliver P Peoples. View insider buying and selling activity for Yield10 Bioscience.

How do I buy shares of Yield10 Bioscience?

Shares of YTEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Yield10 Bioscience's stock price today?

One share of YTEN stock can currently be purchased for approximately $6.00.

How big of a company is Yield10 Bioscience?

Yield10 Bioscience has a market capitalization of $11.82 million and generates $810,000.00 in revenue each year. The specialty chemicals company earns $-12,960,000.00 in net income (profit) each year or ($35.50) on an earnings per share basis. Yield10 Bioscience employs 22 workers across the globe.

What is Yield10 Bioscience's official website?

The official website for Yield10 Bioscience is www.yield10bio.com.

How can I contact Yield10 Bioscience?

Yield10 Bioscience's mailing address is 19 PRESIDENTIAL WAY, WOBURN MA, 01801. The specialty chemicals company can be reached via phone at 617-583-1700 or via email at [email protected]

This page was last updated on 5/31/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.